| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.VIROL.2008.04.005 |
| P8608 | Fatcat ID | release_yuvsduyuwbasldmk565hfmqo6e |
| P932 | PMC publication ID | 2493441 |
| P698 | PubMed publication ID | 18499210 |
| P5875 | ResearchGate publication ID | 5351375 |
| P50 | author | Dennis R. Burton | Q56331320 |
| G. Marius Clore | Q19864601 | ||
| P2093 | author name string | John M Louis | |
| Philip E Dawson | |||
| Douglas D Richman | |||
| Rose G Mage | |||
| Michael B Zwick | |||
| Richard Jensen | |||
| Katherine Bowdish | |||
| Toshiaki Maruyama | |||
| Carole A Bewley | |||
| Florence M Brunel | |||
| Shana Frederickson | |||
| Heather Kinkead | |||
| Josh D Nelson | |||
| Dan Leaman | |||
| P2860 | cites work | The hydrophobic pocket contributes to the structural stability of the N-terminal coiled coil of HIV gp41 but is not required for six-helix bundle formation | Q73325759 |
| Monoclonal antibodies that bind to the core of fusion-active glycoprotein 41 | Q73385332 | ||
| Identification of Anti-Thrombin Antibodies in the Antiphospholipid Syndrome That Interfere with the Inactivation of Thrombin by Antithrombin | Q77337968 | ||
| Exposure of the membrane-proximal external region of HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion | Q79683357 | ||
| Steric accessibility of the HIV-1 gp41 N-trimer region | Q81289318 | ||
| Neutralizing as well as non-neutralizing polyclonal immunoglobulin (Ig)G from infected patients capture HIV-1 via antibodies directed against the principal immunodominant domain of gp41 | Q81396903 | ||
| HIV vaccines | Q82900063 | ||
| Cryo-electron tomographic structure of an immunodeficiency virus envelope complex in situ | Q21090535 | ||
| The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens | Q22242262 | ||
| Three-dimensional solution structure of the 44kDa ectodomain of SIV gp41 | Q24533287 | ||
| Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies | Q24561905 | ||
| Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1 | Q24645530 | ||
| Structural definition of a conserved neutralization epitope on HIV-1 gp120 | Q24655948 | ||
| Potent D-peptide inhibitors of HIV-1 entry | Q24675493 | ||
| Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket | Q27619965 | ||
| Antibody domain exchange is an immunological solution to carbohydrate cluster recognition | Q27641517 | ||
| Core structure of gp41 from the HIV envelope glycoprotein | Q27736064 | ||
| Atomic structure of the ectodomain from HIV-1 gp41 | Q27738021 | ||
| GP120: target for neutralizing HIV-1 antibodies | Q28303124 | ||
| Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region | Q28360391 | ||
| Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection | Q28369033 | ||
| Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target | Q28369397 | ||
| Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion | Q28646673 | ||
| Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype | Q28646874 | ||
| CD4-Induced Conformational Changes in the Human Immunodeficiency Virus Type 1 gp120 Glycoprotein: Consequences for Virus Entry and Neutralization | Q28646881 | ||
| Structure of an unliganded simian immunodeficiency virus gp120 core | Q29616089 | ||
| Mechanisms of viral membrane fusion and its inhibition | Q29616090 | ||
| Distribution and three-dimensional structure of AIDS virus envelope spikes | Q29617562 | ||
| Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody | Q29618366 | ||
| Structure of a V3-containing HIV-1 gp120 core | Q29619014 | ||
| Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies | Q29619015 | ||
| Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1 | Q29619512 | ||
| Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes | Q29619514 | ||
| Human antibodies from immunized donors are protective against anthrax toxin in vivo | Q31011016 | ||
| Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. | Q31016954 | ||
| Rabbit immune repertoires as sources for therapeutic monoclonal antibodies: the impact of kappa allotype-correlated variation in cysteine content on antibody libraries selected by phage display | Q31121743 | ||
| Reassessment of autoreactivity of the broadly neutralizing HIV antibodies 4E10 and 2F5 and retrospective analysis of clinical safety data | Q31140424 | ||
| A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12. | Q31143293 | ||
| Protein design of an HIV-1 entry inhibitor | Q32067748 | ||
| Characterization and HIV-1 fusion inhibitory properties of monoclonal Fabs obtained from a human non-immune phage library selected against diverse epitopes of the ectodomain of HIV-1 gp41. | Q33224942 | ||
| Selection of a novel gp41-specific HIV-1 neutralizing human antibody by competitive antigen panning | Q33262382 | ||
| An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10 | Q33272711 | ||
| Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies | Q33274285 | ||
| Electron tomography of the contact between T cells and SIV/HIV-1: implications for viral entry. | Q33283730 | ||
| A monoclonal Fab derived from a human nonimmune phage library reveals a new epitope on gp41 and neutralizes diverse human immunodeficiency virus type 1 strains. | Q33300529 | ||
| Antibody neutralization-resistant primary isolates of human immunodeficiency virus type 1. | Q33786382 | ||
| Recognition by human monoclonal antibodies of free and complexed peptides representing the prefusogenic and fusogenic forms of human immunodeficiency virus type 1 gp41 | Q33807129 | ||
| Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M. | Q33809112 | ||
| Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers | Q33836042 | ||
| Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection | Q33943822 | ||
| Comparing antigenicity and immunogenicity of engineered gp120. | Q33984309 | ||
| A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope | Q34078521 | ||
| Medicine. The need for a global HIV vaccine enterprise | Q34209402 | ||
| Conformational changes in HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion and inactivation. | Q34225654 | ||
| A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1 | Q34306804 | ||
| Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics | Q34415921 | ||
| Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. | Q34434854 | ||
| Antigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a DNA prime-protein boost immunization strategy | Q35785338 | ||
| Protein grafting of an HIV-1-inhibiting epitope | Q35813478 | ||
| Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. | Q35853750 | ||
| Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors | Q35857221 | ||
| Epitope map of human immunodeficiency virus type 1 gp41 derived from 47 monoclonal antibodies produced by immunization with oligomeric envelope protein | Q35880289 | ||
| V3: HIV's switch-hitter | Q36051661 | ||
| A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120. | Q36149102 | ||
| Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands | Q36296739 | ||
| Increased efficacy of HIV-1 neutralization by antibodies at low CCR5 surface concentration. | Q36496923 | ||
| Role of neutralizing antibodies in protective immunity against HIV. | Q36622477 | ||
| Rational modifications of HIV-1 envelope glycoproteins for immunogen design | Q36725263 | ||
| Human antibody responses to HIV type 1 glycoprotein 41 cloned in phage display libraries suggest three major epitopes are recognized and give evidence for conserved antibody motifs in antigen binding | Q36818811 | ||
| HIV-1 neutralization: mechanisms and relevance to vaccine design | Q37017819 | ||
| Immunogenicity of recombinant human immunodeficiency virus type 1-like particles expressing gp41 derivatives in a pre-fusion state | Q37250899 | ||
| Covalent trimers of the internal N-terminal trimeric coiled-coil of gp41 and antibodies directed against them are potent inhibitors of HIV envelope-mediated cell fusion. | Q38356421 | ||
| Macrophage tropism of human immunodeficiency virus type 1 and utilization of the CC-CKR5 coreceptor. | Q38943221 | ||
| Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization | Q39389791 | ||
| A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the human immunodeficiency virus type 1 envelope glycoprotein. | Q39583441 | ||
| Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies | Q39698363 | ||
| Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies | Q40106699 | ||
| Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. | Q40429324 | ||
| Differential inhibition of HIV-1 and SIV envelope-mediated cell fusion by C34 peptides derived from the C-terminal heptad repeat of gp41 from diverse strains of HIV-1, HIV-2, and SIV. | Q40435668 | ||
| Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. | Q40721814 | ||
| A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. | Q40757568 | ||
| Design and properties of N(CCG)-gp41, a chimeric gp41 molecule with nanomolar HIV fusion inhibitory activity | Q40797427 | ||
| Generation and structural analysis of soluble oligomeric gp140 envelope proteins derived from neutralization-resistant and neutralization-susceptible primary HIV type 1 isolates | Q40869062 | ||
| Length distribution of CDRH3 in antibodies | Q40909294 | ||
| Preparation and characterization of human HIV type 1 neutralizing reference sera | Q41332501 | ||
| Epitope exposure on functional, oligomeric HIV-1 gp41 molecules | Q41381359 | ||
| Generation of Human Monoclonal Antibodies against HIV-1 Proteins; Electrofusion and Epstein-Barr Virus Transformation for Peripheral Blood Lymphocyte Immortalization | Q41478638 | ||
| Changes in growth properties on passage in tissue culture of viruses derived from infectious molecular clones of HIV-1LAI, HIV-1MAL, and HIV-1ELI. | Q41655443 | ||
| HIV-1 inhibition by a peptide | Q42559777 | ||
| Kinetic dependence to HIV-1 entry inhibition | Q43627216 | ||
| The membrane-proximal external region of HIV-1 gp41: a vaccine target worth exploring | Q44830344 | ||
| Biophysical evidence of two docking sites of the carboxyl heptad repeat region within the amino heptad repeat region of gp41 of human immunodeficiency virus type 1. | Q45407807 | ||
| A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120. | Q45409784 | ||
| Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes | Q45411655 | ||
| The production of cleaved, trimeric human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein vaccine antigens and infectious pseudoviruses using linear polyethylenimine as a transfection reagent | Q45417960 | ||
| Immunogenicity and ability of variable loop-deleted human immunodeficiency virus type 1 envelope glycoproteins to elicit neutralizing antibodies | Q45729699 | ||
| Difficulties in eliciting broadly neutralizing anti-HIV antibodies are not explained by cardiolipin autoreactivity | Q46168513 | ||
| Analysis of the HIV-1 gp41 specific immune response using a multiplexed antibody detection assay | Q47728394 | ||
| Expression and characterization of HIV type 1 envelope protein associated with a broadly reactive neutralizing antibody response | Q47968718 | ||
| Anticardiolipin wet workshop report. Fifth International Symposium on antiphospholipid antibodies | Q53383786 | ||
| Analysis of the neutralizing antibody response elicited in rabbits by repeated inoculation with trimeric HIV-1 envelope glycoproteins | Q53877712 | ||
| Structural basis for HIV-1 neutralization by a gp41 fusion intermediate-directed antibody. | Q54040210 | ||
| A trimeric structural domain of the HIV-1 transmembrane glycoprotein | Q54155492 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| P1104 | number of pages | 14 | |
| P304 | page(s) | 170-183 | |
| P577 | publication date | 2008-05-21 | |
| P1433 | published in | Virology | Q7934867 |
| P1476 | title | Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics | |
| P478 | volume | 377 |
| Q33523258 | Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41 |
| Q33495440 | Affinity maturation by targeted diversification of the CDR-H2 loop of a monoclonal Fab derived from a synthetic naïve human antibody library and directed against the internal trimeric coiled-coil of gp41 yields a set of Fabs with improved HIV-1 [...] |
| Q33946158 | Antibody to gp41 MPER alters functional properties of HIV-1 Env without complete neutralization |
| Q35689608 | Binding of Anti-Membrane-Proximal gp41 Monoclonal Antibodies to CD4-Liganded and -Unliganded Human Immunodeficiency Virus Type 1 and Simian Immunodeficiency Virus Virions |
| Q34020570 | Binding of HIV-1 gp41-directed neutralizing and non-neutralizing fragment antibody binding domain (Fab) and single chain variable fragment (ScFv) antibodies to the ectodomain of gp41 in the pre-hairpin and six-helix bundle conformations |
| Q33798076 | Characteristics of the earliest cross-neutralizing antibody response to HIV-1. |
| Q27303525 | Complexes of neutralizing and non-neutralizing affinity matured Fabs with a mimetic of the internal trimeric coiled-coil of HIV-1 gp41 |
| Q27666159 | Crystal Structure and Size-Dependent Neutralization Properties of HK20, a Human Monoclonal Antibody Binding to the Highly Conserved Heptad Repeat 1 of gp41 |
| Q36057328 | Design and characterization of a peptide mimotope of the HIV-1 gp120 bridging sheet |
| Q34489464 | Designing a soluble near full-length HIV-1 gp41 trimer |
| Q92373152 | Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41 |
| Q58601813 | Display of the HIV envelope protein at the yeast cell surface for immunogen development |
| Q33431668 | Efficient recovery of high-affinity antibodies from a single-chain Fab yeast display library |
| Q37739483 | From rabbit antibody repertoires to rabbit monoclonal antibodies |
| Q58555325 | HIV Entry and Its Inhibition by Bifunctional Antiviral Proteins |
| Q37593177 | Identification of Human Anti-HIV gp160 Monoclonal Antibodies That Make Effective Immunotoxins |
| Q33725718 | In-solution virus capture assay helps deconstruct heterogeneous antibody recognition of human immunodeficiency virus type 1 |
| Q34611144 | Increased Functional Stability and Homogeneity of Viral Envelope Spikes through Directed Evolution |
| Q36603515 | Neutralizing antibodies to HIV-1 induced by immunization. |
| Q50943628 | Novel neutralising antibodies targeting the N-terminal helical region of the transmembrane envelope protein p15E of the porcine endogenous retrovirus (PERV) |
| Q30436401 | Oligomer-specific conformations of the human immunodeficiency virus (HIV-1) gp41 envelope glycoprotein ectodomain recognized by human monoclonal antibodies |
| Q34273397 | Phages and HIV-1: from display to interplay |
| Q39141826 | Polyclonal Antibody Against Conserved Peptide in Transmembrane Protein of Avian Leukosis Virus Subgroup J |
| Q36228646 | Receptor Activation of HIV-1 Env Leads to Asymmetric Exposure of the gp41 Trimer. |
| Q40088729 | Recombinant Origins of Pathogenic and Nonpathogenic Mouse Gammaretroviruses with Polytropic Host Range |
| Q38046828 | Role of human immunodeficiency virus type 1 envelope structure in the induction of broadly neutralizing antibodies. |
| Q33567639 | SERINC5 protein inhibits HIV-1 fusion pore formation by promoting functional inactivation of envelope glycoproteins. |
| Q33356323 | Sequestering of the prehairpin intermediate of gp41 by peptide N36Mut(e,g) potentiates the human immunodeficiency virus type 1 neutralizing activity of monoclonal antibodies directed against the N-terminal helical repeat of gp41 |
| Q27665960 | Structural Basis of HIV-1 Neutralization by Affinity Matured Fabs Directed against the Internal Trimeric Coiled-Coil of gp41 |
| Q35122067 | Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1 |
| Q34778515 | Sub-Inhibitory Concentrations of Human α-defensin Potentiate Neutralizing Antibodies against HIV-1 gp41 Pre-Hairpin Intermediates in the Presence of Serum |
| Q40387378 | The C34 Peptide Fusion Inhibitor Binds to the Six-Helix Bundle Core Domain of HIV-1 gp41 by Displacement of the C-Terminal Helical Repeat Region |
| Q33935016 | Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates |
Search more.